Rapid Micro Biosystems, Inc

Rapid Micro Biosystems has a market capitalization of $117.16 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is characterized by $20.03 million in cash and equivalents, which is a significant portion of its total assets of $74.85 million. However, the company reported negative operating and net income of $47.39 million and $47.12 million, respectively, in the latest period. The company's profitability is underperforming relative to industry standards, as evidenced by a return on equity of -141.91% and a return on assets of -62.95%. These figures suggest that the company is not generating returns that meet the cost of capital for either equity or total assets. The gross profit of $1.05 million is significantly lower than the company's operating expenses, contributing to the net loss. Geographically and segment-wise, the company's exposure is not disclosed in the available data. However, the company's revenue of $33.59 million is concentrated in a single business line, which could pose a concentration risk if demand for its products declines or if the company fails to expand into new markets. The company's growth trajectory is currently negative, with a significant operating loss and negative cash flows from operations of $31.06 million. The capital expenditure of $850,000 indicates that the company is investing in its operations, but the negative free cash flow of $44.72 million suggests that the company is not generating enough cash to sustain operations without external financing. The risk assessment indicates a low level of liquidity risk, but the company's debt-to-equity ratio of 0.57 suggests that it is not overly leveraged. The risk of dilution is also assessed as low, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is supported by $19.09 million in long-term debt and $41.65 million in total liabilities, which is offset by $33.21 million in total equity. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's stock is currently trading at $2.56, and analyst estimates suggest a mean price target of $8.00, indicating a potential upside of 212% from the current price. The mean recommendation of 1.75 suggests a generally positive outlook from analysts, with one strong-buy and three buy ratings.